Clinical Trials
A Purposeful approach
Advancing patient-centric solutions
We are focused on creating immunotherapies with the goal of meaningfully improving the lives of people with cancer.
Mural Oncology is conducting clinical trials of investigational nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy, in difficult-to-treat cancers with high unmet needs.
Learn About
Our Clinical Trials
At Mural Oncology, our unwavering commitment lies in continuously pushing the boundaries of cancer research, seeking transformative breakthroughs. Our efforts extend across the nation, conducting trials that pave the way for a brighter future in cancer care.
-7
ARTISTRY-7 is a global, Phase 3, randomized, open-label study evaluating the anti-tumor activity and safety of intravenous (IV) nemvaleukin in combination with pembrolizumab compared to investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer (PROC).
Status
Recruiting
More Information
Use the links below to access resources with additional information about this study.
-6
ARTISTRY-6 is a global, Phase 2, multicenter, open-label study evaluating nemvaleukin monotherapy in patients with advanced mucosal or cutaneous melanoma who have received prior treatment with an anti–PD-L1 therapy with or without anti-cytotoxic T lymphocyte associated antigen 4 (CTLA-4) therapy.
Status
Recruiting
More Information
Use the links below to access resources with additional information about this study.
-3
ARTISTRY-3 is a Phase 1/2 open-label study of IV nemvaleukin in patients with advanced solid tumors. Cohort 2 of ARTISTRY-3 is evaluating the safety and tolerability of higher doses of IV nemvaleukin administered on a less frequent IV dosing schedule of one or two doses per three-week cycle.
Status
Active, Not Recruiting
More Information
Use the link below to access resources with additional information about this study.
Discover
Expanded Access Program
Mural Oncology’s goal is to efficiently bring safe and effective medicines to all appropriate patients by conducting rigorous clinical trials and obtaining marketing approval by regulatory authorities, including the U.S. Food and Drug Administration (FDA). Prior to such approval, participation in one of our clinical trials is the optimal way for patients to gain access to our investigational medicines. However, we understand that some patients may not be able to participate in a clinical trial and may seek access to investigational treatments before they are approved. If early data from preclinical and clinical trials suggest that an investigational treatment can offer benefits for patients facing serious or life-threatening conditions, Mural Oncology may consider requests to provide access outside of a clinical study. The link below provides further information about the Mural Oncology Expanded Access Program.